These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30948274)

  • 1. Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
    Marchetti C; Fagotti A; Scambia G
    Lancet Oncol; 2019 May; 20(5):603-605. PubMed ID: 30948274
    [No Abstract]   [Full Text] [Related]  

  • 2. How to start niraparib in real-world Asian ovarian cancer patients?
    Hong SH
    J Gynecol Oncol; 2021 Mar; 32(2):e36. PubMed ID: 33559417
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niraparib: First Global Approval.
    Scott LJ
    Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitors in Ovarian Cancer.
    da Costa A
    N Engl J Med; 2020 Apr; 382(16):1572-1573. PubMed ID: 32294361
    [No Abstract]   [Full Text] [Related]  

  • 7. Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
    Lee CS; Kwak SW; Kim YJ; Lee SA; Park ES; Myung SC; Kim W; Lee MS; Lee JJ
    Eur J Pharmacol; 2012 May; 683(1-3):54-62. PubMed ID: 22465181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Medicine for Primary Treatment of Serous Ovarian Cancer.
    Longo DL
    N Engl J Med; 2019 Dec; 381(25):2471-2474. PubMed ID: 31851805
    [No Abstract]   [Full Text] [Related]  

  • 9. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors and quality of life in ovarian cancer.
    Aoki D; Chiyoda T
    Lancet Oncol; 2018 Aug; 19(8):1012-1014. PubMed ID: 30026001
    [No Abstract]   [Full Text] [Related]  

  • 11. PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    Konstantinopoulos PA; Matulonis UA
    Clin Cancer Res; 2018 Sep; 24(17):4062-4065. PubMed ID: 29871906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
    McQueen RB; Whittington MD; Chapman RH; Kumar VM; Campbell JD
    Pharmacoeconomics; 2019 Jul; 37(7):963-964. PubMed ID: 31044348
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
    Guy H; Walder L; Fisher M
    Pharmacoeconomics; 2019 Jul; 37(7):965-967. PubMed ID: 31044349
    [No Abstract]   [Full Text] [Related]  

  • 14. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors for ovarian cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
    [No Abstract]   [Full Text] [Related]  

  • 16. Comment on: "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".
    Wallace K; Goble S; Isaacson J; Maloney L; Cameron T; Bedel J
    Pharmacoeconomics; 2019 Aug; 37(8):1065-1067. PubMed ID: 31172449
    [No Abstract]   [Full Text] [Related]  

  • 17. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR; Bergmann TK; Mau-Sørensen M; Christensen RD; Åvall-Lundqvist E; Birrer MJ; Jørgensen M; Roed H; Malander S; Nielsen F; Lassen U; Brøsen K; Bjørge L; Mäenpää J
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):791-798. PubMed ID: 31375879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
    Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.